Esomenur L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief and promoting mucosal healing in acid-related conditions. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, optimizing efficacy and patient compliance. Esomenur L Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and peptic ulcer disease, particularly in cases where impaired gastric motility and acid hypersecretion coexist. It is essential to administer this medication under medical supervision, considering contraindications such as hypersensitivity to components, and to monitor for potential adverse effects including extrapyramidal symptoms, headache, and gastrointestinal disturbances. Dose adjustments may be necessary in patients with hepatic or renal impairment. This combination therapy offers a synergistic approach to managing complex gastrointestinal conditions by addressing both motility and acid secretion abnormalities.